SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Karyopharm Reports FDA Approval For XPOVIO (Selinexor) For Treatment Of Patients With Relapsed, Refractory Diffuse Large B-Cell Lymphoma

Benzinga · -